MK-677 muscle and GH claims: what the evidence actually shows
Quick answer
MK-677 (ibutamoren) is a non-peptide ghrelin receptor agonist that stimulates pulsatile GH secretion and downstream IGF-1 production. It has been studied in clinical trials for muscle wasting, GH deficiency, and age-related decline, but carries documented metabolic side effects including insulin resistance and elevated fasting glucose (Nass et al., 2008). Use in adolescents is not clinically evaluated and poses theoretical risks to still-developing endocrine axes and growth plate signaling.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @armonadibi actually say?
The creator gave a direct answer to a viewer asking about starting MK-677 at 16: "No, absolutely not." He also claimed that unusual side effects people blame on MK-677 are caused by tainted products spiked with prohormones or SARMs, not the compound itself. He promoted his own MK-677 product, Ceromax, dosed at 25 mg per pill, calling it "pure" and "dosed correctly." He also argued that young lifters should build a natural base before touching any compounds, citing his own path to 240 pounds without gear.
The core factual claims here are: MK-677 should not be used at 16, the supplement market for MK-677 is frequently adulterated, and the compound has a specific, predictable side effect profile when it is pure. He also offers coaching, and the self-promotional framing matters when evaluating objectivity.
Does the science back this up?
On the age question, yes. The concern is legitimate and grounded in biology, though the creator does not explain why. MK-677 (ibutamoren) is a ghrelin receptor agonist that stimulates growth hormone secretion. In adolescents, the hypothalamic-pituitary axis and growth plates are still developing, and exogenously spiking GH pulses during this window carries real theoretical risks to endocrine maturation.
On adulteration, he is on solid ground. A 2017 study by Abbate et al. in Drug Testing and Analysis analyzed 44 SARM and peptide products sold online and found that only 52% contained the labeled compound, and a significant portion contained undisclosed active ingredients including prohormones. A 2021 USADA-cited analysis reinforced that MK-677 products are among the more frequently mislabeled in the gray-market supplement space. His claim that unexpected side effects often point to contamination rather than pure MK-677 is consistent with this data.
The 25 mg dose claim is where things get more complicated. Clinical studies have used doses ranging from 10 to 50 mg, so 25 mg is within studied ranges, but presenting a specific dose as simply "correct" papers over meaningful individual variability.
What did they get wrong (or right)?
Credit where it is due: the age recommendation is right, the adulteration warning is real, and encouraging young lifters to train naturally before adding compounds is sensible advice backed by physiology. Adolescent resistance training produces robust adaptations without hormonal augmentation, and stacking compounds on top of a developmental system you do not fully understand yet is a bad trade.
What he got wrong, or at least oversimplified: his framing that pure MK-677 produces no unexpected side effects is too clean. Even in controlled clinical settings, MK-677 has been associated with increased fasting glucose, insulin resistance, and edema. A randomized controlled trial by Nass et al. (2008, Annals of Internal Medicine) specifically flagged increased insulin resistance as a concern. These are not contamination artifacts. They are pharmacological effects of the compound itself. Saying side effects "do not come from MK-677" without qualification is misleading.
His product promotion is also a conflict of interest that should be named. Recommending against a compound in 16-year-olds while selling that same compound in the same video is a tension worth noting.
What should you actually know?
MK-677 is not FDA-approved for any indication. It is classified as an investigational drug and is banned by WADA. Purchasing it exists in a legal gray zone depending on jurisdiction, and quality control in the gray market is genuinely poor. The adulteration data is real, and it matters.
For anyone considering MK-677 as an adult, the honest picture includes documented risks: elevated blood glucose, water retention, increased appetite beyond what some users want, and the unknown long-term effects of chronically elevated GH and IGF-1. The longevity implications of sustained IGF-1 elevation are debated, not resolved. Some cancer biology research raises questions about long-term IGF-1 stimulation, though no causal human evidence currently links therapeutic-range MK-677 use to cancer outcomes.
Age 16 is not the only line. Anyone with a personal or family history of glucose dysregulation, insulin resistance, or hormone-sensitive conditions should discuss this class of compound with an endocrinologist before considering it, regardless of age.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For MK-677 muscle and GH claims: what the evidence actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Ipamorelin, the first selective growth hormone secretagogue
Background source for ipamorelin selectivity and GH-secretagogue mechanism.
PubMed
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation
Preclinical context that should not be overstated as consumer clinical evidence.
PubMed
GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis
Used for PCOS pages comparing metabolic and weight-management approaches.
PubMed
The efficacy and safety of GLP-1 agonists in PCOS women living with obesity
Supports PCOS, obesity, and hormonal-regulation context.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
MK-677 muscle and GH claims: what the evidence actually shows is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
MK-677 (ibutamoren) is a non-peptide ghrelin receptor agonist that stimulates pulsatile GH secretion and downstream IGF-1 production.
FormBlends verdict
MK-677 (ibutamoren) is a non-peptide ghrelin receptor agonist that stimulates pulsatile GH secretion and downstream IGF-1 production. It has been studied in clinical trials for muscle wasting, GH deficiency, and age-related decline, but carries documented metabolic side effects including insulin resistance and elevated fasting glucose (Nass et al., 2008). Use in adolescents is not clinically evaluated and poses theoretical risks to still-developing endocrine axes and growth plate signaling.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- MK-677 (ibutamoren) is a non-peptide ghrelin receptor agonist that stimulates pulsatile GH secretion and downstream IGF-1 production. It has been studied in clinical trials for muscle wasting, GH deficiency, and age-related decline, but carries documented metabolic side effects including insulin resistance and elevated fasting glucose (Nass et al., 2008). Use in adolescents is not clinically evaluated and poses theoretical risks to still-developing endocrine axes and growth plate signaling.
- MK-677 is not FDA-approved and is banned by WADA; purchasing it in the United States occupies a legal gray area with no regulatory quality oversight.
- A 2017 Drug Testing and Analysis study (Abbate et al.) found only 52% of sampled SARM and peptide products online contained what their labels claimed, supporting the adulteration concern raised in the video.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- MK-677 is not FDA-approved and is banned by WADA; purchasing it in the United States occupies a legal gray area with no regulatory quality oversight.
- A 2017 Drug Testing and Analysis study (Abbate et al.) found only 52% of sampled SARM and peptide products online contained what their labels claimed, supporting the adulteration concern raised in the video.
- A randomized controlled trial (Nass et al., 2008, Annals of Internal Medicine) found MK-677 increased insulin resistance and fasting glucose even at studied doses in older adults, independent of product purity.
- No clinical trials have evaluated MK-677 safety or efficacy in individuals under 18; use in adolescents with developing endocrine systems has no evidence base and meaningful theoretical risk.
- Long-term consequences of sustained IGF-1 elevation from GH secretagogues remain unresolved; cancer biology research has raised questions about chronic IGF-1 stimulation, though no causal human evidence currently exists for this class at therapeutic doses.
- The creator selling the same compound he advises against for minors is a direct conflict of interest that viewers should factor into how they weigh his product-specific claims.
- Water retention and increased appetite are pharmacological effects of MK-677 itself, not contamination markers; framing all adverse effects as a product quality issue understates the compound's real side effect profile.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Armon Adibi · TikTok creator
81.4K views on this video
Replying to @¿ #amglabz #wickepumps #prepcoach #ironogs #supplementsthatwork #adibiarmy #coach #natty #enhanced #hypertrophy #gymtime #ifbb #npc #fitafter40 #ripped #openbodybuilding #wellness #amazon #gda #convey #openbodybuilding #gearedup #fitness #hypertrophy #dnpburn #mk677
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Armon Adibi, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.